An important factor in Win Medica’s success is the strategic agreements it has concluded with renowned multinational pharmaceutical companies.
Win Medica is strengthening its activity in specific areas of the pharmaceutical market and our portfolio mainly covers, but not limited to, the Greek area. Apart from Europe, the company plans to expand into other emerging foreign markets that are substantial business opportunities with partnerships with reputable partners.
Focused exclusively on and leading in growing healthcare sectors, Novartis has an expanded product portfolio: innovative proprietary pharmaceuticals, cost-effective generics, vaccines and diagnostics, as well as over-the-counter medicines. Headquartered in Basel, Switzerland, Novartis Group companies employ 98,000 people and operate in more than 140 countries around the world.
Seqirus is one of the leading companies in the development and distribution of influenza vaccines worldwide. Its high quality and efficiency products are available in 35 countries worldwide. The plant in the United States (Holly Springs) is the largest vaccine plant in the world, is a joint venture with the US Government to treat the flu pandemic and has the capacity to produce> 150 million doses within 6 months in case of a flu pandemic.
Polpharma is ranked among the top 20 pharmaceutical manufacturers in the world, with sales of USD 1 billion per year. It employs over 7,000 people in Poland and international markets. It has 7 production plants in Poland, Russia and Kazakhstan and 6 research and development centers. Polpharma Group's portfolio includes 600 products and another 200 products which are currently under development.
Pharmanutra SpA is a pharmaceutical company based in Pisa, founded in 2003 for the development of nutraceuticals and medical devices. It follows strict quality standards, always making the selection of the raw materials it uses one of its top priorities, so that they are uniquely and exclusively selected for the national market.
Welding GmbH & CO. KG was founded in 1955 and is privately owned. With headquarters in Hamburg, sales offices in Frankfurt and a subsidiary in Lyon, France, the company currently employs more than 120 people. Its areas of activity: • Trading of active ingredients, excipients and natural substances for human and veterinary medicines • Development, licensing and promotion of generic medicines • Commercialization of food and feed additives • Provision of an extensive range of services covering the areas of quality management, promotion and regulatory affairs.
The French company Servier founded in 1954 and today is the first French independent pharmaceutical group. Servier is present in 149 countries, with more than 22,000 employees, of which 3,000 in Research and has been active in Greece since 1977.
Viatris Hellas has emerged from the merge of Mylan and Upjohn, a company of the Pfizer group, with the goal of better access to treatments. Viatris offers a diversified portfolio of medicines, including original, generic and bioequivalent products as well as OTC & Pharmacy products.
Accord Healthcare is an established Genomics and Biotechnology Pharmaceutical company, which is active in the development, production and distribution of pharmaceutical products in over 80 countries around the world, including the United States and Canada. In Europe, Accord Healthcare started its commercial activity in 2008 and currently has over 9,300 marketing authorizations in European countries.
MAbxience is a Spanish international high-tech biotechnology company specializing in the research, development, production and marketing of biotechnology products for the treatment and prevention of diseases in various therapeutic fields. Have access to quality products around the world, as well as the supply of affordable and cost-effective medicines to healthcare systems worldwide.
Chemo is a large pharmaceutical company with 5,000 employees who are entirely dedicated to improving health. Chemo operates mainly in 3 business areas: • Industrial • Commercial • Biotechnology Chemo continues to expand its efforts and invest in R&D to develop new and improved therapeutic solutions.
Medis is a global business partner in over 140 countries. It specializes in the development of high quality generic pharmaceuticals. Medis offers a broad product portfolio to pharmaceutical companies. It provides approximately 200 pharmaceutical products for human use, mainly in the pharmacopoeia form of tablets, capsules and injectables.
Sofar S.p.A., an Italian company, produces high quality pharmaceutical products, nutritional supplements and medical devices. Operating for over 45 years in the pharmaceutical sector, Sofar's extensive knowledge of the market allows it to look ahead to the future, taking advantage of its experience, resulting in a specialized and mature presence, characterized by innovative solutions.
The Adamed Group was created to support research and development, as well as academic and educational activity in the field of natural sciences. Complying with even the most stringent European standards, its products are currently available in 60 markets around the world including Europe, Australia, New Zealand, South America, Africa, Asia and the Middle East.